Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial (Q33372127)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial |
scientific article |
Statements
1 reference
Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial (English)
1 reference
Giovanni Scambia
1 reference
Antonella Savarese
1 reference
Enrico Breda
1 reference
Paolo Scollo
1 reference
Rocco De Vivo
1 reference
Emanuela Rossi
1 reference
Donato Natale
1 reference
Filomena Del Gaizo
1 reference
Emanuele Naglieri
1 reference
Antonella Ferro
1 reference
Pietro Musso
1 reference
Alfonso Maria D'Arco
1 reference
Roberto Sorio
1 reference
Carmela Pisano
1 reference
Annalisa Annunziata
1 reference
Francesco Perrone
1 reference
MITO Investigators
1 reference
1 August 2006
1 reference
1 reference
202
1 reference
1 August 2006
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference